1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Early Data On Amgen’s AMG 133 Show Potential Durability, Dosing Advantage In Obesity

 
• By Alaric DeArment

The drug is dosed once every four weeks – compared with Mounjaro and Wegovy’s weekly dosing – but the company also signaled it is considering extended dosing intervals.

Amgen announced data on AMG 133 in obesity • Source: Shutterstock

It’s still early days, but the first set of data on Amgen, Inc.’s bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule, AMG 133, suggest it could gain an advantage on the market with its efficacy, durability and less frequent dosing in treating obesity than competing drugs.

Amgen presented data for AMG 133 on 3 December at the World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) from its first-in-human Phase I trial among patients who have obesity without

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 
• By Dexter Jie Yan

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

More from R&D

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.